The currently available TBEV vaccines suffer from some disadvantages as discussed above,including: (a) the time-consuming vaccination regimen and need of regular booster vaccinations formaintaining the protective efficacy, (b) reduced immunogenicity in the elderly as well as (c) vaccination breakthrough infections and non-responders (vaccine failure). Therefore, the development of improved vaccines against TBEV is desirable. An ideal TBEV vaccine should fulfill several requirements: